Efficacy and safety of casirivimab/imdevimab (REGEN-COV) in pregnant individuals with COVID-19: Literature review and insights from the COVID-19 International Drug Pregnancy Registry
Obstetric Medicine: The Medicine of Pregnancy
Published online on June 09, 2025
Abstract
Obstetric Medicine, Volume 19, Issue 2, Page 89-97, June 2026.
IntroductionCasirivimab/imdevimab (CAS/IMD) comprises two monoclonal antibodies that neutralize SARS-CoV-2. Pregnant individuals were excluded from initial trials, limiting safety data.MethodsThe COVID-19 International Drug Pregnancy Registry enrolled 53 ...
IntroductionCasirivimab/imdevimab (CAS/IMD) comprises two monoclonal antibodies that neutralize SARS-CoV-2. Pregnant individuals were excluded from initial trials, limiting safety data.MethodsThe COVID-19 International Drug Pregnancy Registry enrolled 53 ...